[
  {
    "ts": null,
    "headline": "Merck Recommends Rejection of TRC Capital’s \"Mini-Tender\" Offer",
    "summary": "RAHWAY, N.J., November 22, 2024--Merck Recommends Rejection of TRC Capital’s \"Mini-Tender\" Offer",
    "url": "https://finnhub.io/api/news?id=429c586b24f88838d8dde61f6134c6fe7116877a10c5376c9cd001e8b7f87401",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732310220,
      "headline": "Merck Recommends Rejection of TRC Capital’s \"Mini-Tender\" Offer",
      "id": 131572762,
      "image": "https://media.zenfs.com/en/business-wire.com/5b167dd97d723208185ea68db1badbf8",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 22, 2024--Merck Recommends Rejection of TRC Capital’s \"Mini-Tender\" Offer",
      "url": "https://finnhub.io/api/news?id=429c586b24f88838d8dde61f6134c6fe7116877a10c5376c9cd001e8b7f87401"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a580143eb795ec6445c91757cfbeeec085190a757111e732a636ed56d5e3e5a5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293300,
      "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "id": 131599255,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a580143eb795ec6445c91757cfbeeec085190a757111e732a636ed56d5e3e5a5"
    }
  },
  {
    "ts": null,
    "headline": "Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer",
    "summary": "Merck , known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation has commenced an unsolicited “mini-tender” offer, dated November 12, 2024, to...",
    "url": "https://finnhub.io/api/news?id=623c944958eb2f03b7f42714865346f2dcd1ea17e5cea35f03ef012ec50de96a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732292283,
      "headline": "Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer",
      "id": 131572097,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck , known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation has commenced an unsolicited “mini-tender” offer, dated November 12, 2024, to...",
      "url": "https://finnhub.io/api/news?id=623c944958eb2f03b7f42714865346f2dcd1ea17e5cea35f03ef012ec50de96a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
    "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
    "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732288243,
      "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
      "id": 131571049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153992734/image_2153992734.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
      "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381"
    }
  },
  {
    "ts": null,
    "headline": "Merck : Surendralal Karsanbhai Elected to Merck Board of Directors Form 8 K",
    "summary": "Surendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J., Nov. 22, 2024 - Merck , known as MSD outside of the United States and Canada, today announced that Surendralal...",
    "url": "https://finnhub.io/api/news?id=fd56f9d91f828c71db2f9222e0e5e7f377c112f1b20e26d76f7980c3c6ffc641",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732285925,
      "headline": "Merck : Surendralal Karsanbhai Elected to Merck Board of Directors Form 8 K",
      "id": 131570077,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Surendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J., Nov. 22, 2024 - Merck , known as MSD outside of the United States and Canada, today announced that Surendralal...",
      "url": "https://finnhub.io/api/news?id=fd56f9d91f828c71db2f9222e0e5e7f377c112f1b20e26d76f7980c3c6ffc641"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=602e4ddc6509b73a1403d647421b9d8f4bf1855f7880af0f0dd11beaa10281fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732284017,
      "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
      "id": 131566694,
      "image": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=602e4ddc6509b73a1403d647421b9d8f4bf1855f7880af0f0dd11beaa10281fc"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference",
    "summary": "RAHWAY, N.J., November 22, 2024--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference",
    "url": "https://finnhub.io/api/news?id=1de7b7861f993fb85a70d057150d9e1acffa615af0ddb122be18d2bba43bde2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732277700,
      "headline": "Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference",
      "id": 131566697,
      "image": "https://media.zenfs.com/en/business-wire.com/e2ca6f15c316de3511e0995d7dfcd2ac",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 22, 2024--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference",
      "url": "https://finnhub.io/api/news?id=1de7b7861f993fb85a70d057150d9e1acffa615af0ddb122be18d2bba43bde2e"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors",
    "summary": "RAHWAY, N.J., November 22, 2024--Merck’s WELIREG Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors",
    "url": "https://finnhub.io/api/news?id=6e23c8e93af2f67ab56afac929649a69925f2b3c2708c8808e38727c2d7a48c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732275900,
      "headline": "Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors",
      "id": 131562004,
      "image": "https://media.zenfs.com/en/business-wire.com/a449b3b3a04ff3e8456697f6b273250c",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 22, 2024--Merck’s WELIREG Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors",
      "url": "https://finnhub.io/api/news?id=6e23c8e93af2f67ab56afac929649a69925f2b3c2708c8808e38727c2d7a48c8"
    }
  },
  {
    "ts": null,
    "headline": "Surendralal Karsanbhai Elected to Merck Board of Directors",
    "summary": "RAHWAY, N.J., November 22, 2024--Surendralal Karsanbhai Elected to Merck Board of Directors",
    "url": "https://finnhub.io/api/news?id=36bbe1bb1add6816260c1f4c6d250609fb313ce5c25e4874cffe4899b850f5af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732275000,
      "headline": "Surendralal Karsanbhai Elected to Merck Board of Directors",
      "id": 131562005,
      "image": "https://media.zenfs.com/en/business-wire.com/3947a1d5c56af8ec1dca26d23b313264",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 22, 2024--Surendralal Karsanbhai Elected to Merck Board of Directors",
      "url": "https://finnhub.io/api/news?id=36bbe1bb1add6816260c1f4c6d250609fb313ce5c25e4874cffe4899b850f5af"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock",
    "summary": "We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future […]",
    "url": "https://finnhub.io/api/news?id=5267a96a00dc57c19e47411b70cd6129177438008fdecae658e0c02a8c2f897b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732274391,
      "headline": "Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock",
      "id": 131562007,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future […]",
      "url": "https://finnhub.io/api/news?id=5267a96a00dc57c19e47411b70cd6129177438008fdecae658e0c02a8c2f897b"
    }
  },
  {
    "ts": null,
    "headline": "Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store",
    "summary": "Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK appointment. Click for my MRNA stock update.",
    "url": "https://finnhub.io/api/news?id=a186971be94e6075116e7eab2f5a60a76297e5fec842b0e96f1fe77dc43feff0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732273623,
      "headline": "Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store",
      "id": 131566035,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182853884/image_1182853884.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK appointment. Click for my MRNA stock update.",
      "url": "https://finnhub.io/api/news?id=a186971be94e6075116e7eab2f5a60a76297e5fec842b0e96f1fe77dc43feff0"
    }
  },
  {
    "ts": null,
    "headline": "Top US Dividend Stocks To Consider In November 2024",
    "summary": "As the U.S. stock market continues its upward trajectory, with the S&P 500 extending its winning streak and major indices nearing record highs, investors are increasingly looking for stable income sources amidst this bullish environment. In such times, dividend stocks can provide a reliable stream of income while potentially benefiting from capital appreciation, making them an attractive option for investors seeking to balance growth with stability in their portfolios.",
    "url": "https://finnhub.io/api/news?id=3ee96cbaa5ca50b31b86dc7d8c50c44838490b9c8204c145f1243969541be69a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732273442,
      "headline": "Top US Dividend Stocks To Consider In November 2024",
      "id": 131562012,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/a192a90509b207df974cc973e0c18172",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As the U.S. stock market continues its upward trajectory, with the S&P 500 extending its winning streak and major indices nearing record highs, investors are increasingly looking for stable income sources amidst this bullish environment. In such times, dividend stocks can provide a reliable stream of income while potentially benefiting from capital appreciation, making them an attractive option for investors seeking to balance growth with stability in their portfolios.",
      "url": "https://finnhub.io/api/news?id=3ee96cbaa5ca50b31b86dc7d8c50c44838490b9c8204c145f1243969541be69a"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-US FDA finds widely used asthma drug impacts the brain",
    "summary": "U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.  The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.  Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler.",
    "url": "https://finnhub.io/api/news?id=104f8c484fb040fb6762a62632f8478b41828ff261de6e24d57d647b43faab26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732273428,
      "headline": "Exclusive-US FDA finds widely used asthma drug impacts the brain",
      "id": 131562013,
      "image": "https://media.zenfs.com/en/reuters-finance.com/71b9dafcb543faedb07ae003e80355f5",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.  The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.  Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler.",
      "url": "https://finnhub.io/api/news?id=104f8c484fb040fb6762a62632f8478b41828ff261de6e24d57d647b43faab26"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Mutual Shares Fund Q3 2024 Commentary",
    "summary": "US equities, as measured by the Russell 1000 Index, rose in the third quarter of 2024. Read more here.",
    "url": "https://finnhub.io/api/news?id=2f8a83e2c992e2cb176e3aaa299935b0471d1679fc7442f6dcea1a5d65f881eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732268400,
      "headline": "Franklin Mutual Shares Fund Q3 2024 Commentary",
      "id": 131564706,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/869012362/image_869012362.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "US equities, as measured by the Russell 1000 Index, rose in the third quarter of 2024. Read more here.",
      "url": "https://finnhub.io/api/news?id=2f8a83e2c992e2cb176e3aaa299935b0471d1679fc7442f6dcea1a5d65f881eb"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Emerson Electric CEO to join board",
    "summary": "Merck announced today that Surendralal L. 'Lal' Karsanbhai, Managing Director of Emerson Electric Co. will join its Board of Directors effective January 1, 2025. He will be elected by the company's...",
    "url": "https://finnhub.io/api/news?id=1d506bd820295a0c5f31f4f74158fa6624d8dcc9880bcaf2a7f1ab1bed5e28a9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732266019,
      "headline": "Merck: Emerson Electric CEO to join board",
      "id": 131564008,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced today that Surendralal L. 'Lal' Karsanbhai, Managing Director of Emerson Electric Co. will join its Board of Directors effective January 1, 2025. He will be elected by the company's...",
      "url": "https://finnhub.io/api/news?id=1d506bd820295a0c5f31f4f74158fa6624d8dcc9880bcaf2a7f1ab1bed5e28a9"
    }
  },
  {
    "ts": null,
    "headline": "Merck: green light for Welireg in China for VHL disease",
    "summary": "Merck announces that the National Medical Products Administration in China has approved Welireg for the treatment of adults with von Hippel-Lindau disease presenting with clear cell renal cell...",
    "url": "https://finnhub.io/api/news?id=c76e5b58977e93c334c4a7a67a900c68193e3d1b385a0ad43a2ba2e01f776c80",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732265001,
      "headline": "Merck: green light for Welireg in China for VHL disease",
      "id": 131563698,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the National Medical Products Administration in China has approved Welireg for the treatment of adults with von Hippel-Lindau disease presenting with clear cell renal cell...",
      "url": "https://finnhub.io/api/news?id=c76e5b58977e93c334c4a7a67a900c68193e3d1b385a0ad43a2ba2e01f776c80"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Broadcom, Merck, Qualcomm and Natural Health",
    "summary": "Broadcom, Merck, Qualcomm and Natural Health are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=7dec8df4944017ae5763e7563b0b69f406b5228d2c5d8d872b7edc20849b74bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732263180,
      "headline": "The Zacks Analyst Blog Highlights Broadcom, Merck, Qualcomm and Natural Health",
      "id": 131562016,
      "image": "https://media.zenfs.com/en/zacks.com/11c57bc89878c9157e259fddcb0b1629",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Broadcom, Merck, Qualcomm and Natural Health are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=7dec8df4944017ae5763e7563b0b69f406b5228d2c5d8d872b7edc20849b74bc"
    }
  },
  {
    "ts": null,
    "headline": "Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value",
    "summary": "Read more on the real value in high-yield dividend stocks that provide consistent returns and build wealth over time, without getting caught up in market hype.",
    "url": "https://finnhub.io/api/news?id=f16382cc4afa5465a0826753bfc1f70c56973440d0da901827309763ad39686b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732260600,
      "headline": "Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value",
      "id": 131562521,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211987644/image_1211987644.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read more on the real value in high-yield dividend stocks that provide consistent returns and build wealth over time, without getting caught up in market hype.",
      "url": "https://finnhub.io/api/news?id=f16382cc4afa5465a0826753bfc1f70c56973440d0da901827309763ad39686b"
    }
  }
]